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Abstract
Purpose The known importance of testosterone for the
development of benign prostatic hyperplasia (BPH)
prompted us to test the hypothesis whether polymorphisms
of two genes (CYP19A1 and CYP3A4) involved in testos-
terone metabolism are associated with clinical BPH-param-
eters.
Methods A random sample of the population-based Herne
lower urinary tract symptoms cohort was analysed. All
these men underwent a detailed urological work-up. Two
polymorphisms in the CYP19A1 gene [rs700518 in exon 4
(A57G); rs10046 at the 3UTR(C268T)] and one in the
3UTR of CYP3A4 [rs2740574 (A392G)] were determined
by TaqMan assay from genomic DNA of peripheral blood.
These polymorphisms were correlated to clinical and labo-
ratory BPH-parameters.
Results A total of 392 men (65.4 § 7.0 years; 52–79
years) were analysed. Mean International Prostate Symp-
tom Score (IPSS; 7.5), Qmax (15.4 ml/s), prostate volume
(31 ml) and prostate speciWc antigen (PSA) (1.8 ng/ml)
indicated a typical elderly population. Both polymorphisms
in the CYP19A1 gene were not correlated to age, IPSS,
Qmax, prostate volume and post-void residual volume.
Serum PSA was higher in men carrying the heterozygous
rs10046 genotype (2.0 § 0.1 ng/ml) than in those with the
CC-genotype (1.7 § 0.2 ng/ml,  P = 0.012). Men carrying
one a mutated allele of the CYP3A4 gene had smaller pros-
tates (27.0 § 2.0 vs. 32 § 0.8 ml, P = 0.02) and lower PSA
levels (1.6 § 0.3 vs. 1.9 § 0.1 ng/ml).
Conclusions The inconsistent associations observed
herein and for other gene polymorphisms warrant further
studies. In general, the data regarding the association of
gene polymorphism to BPH-parameters suggest that this
disease is caused by multiple rather than a single genetic
variant. A rigorous patient selection based on anatomo-
pathological and hormonal proWle may possible reduce the
number of confounders for future studies thus enabling a
more detailed assessment of the association between
genetic factors and BPH-parameters.
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(BPO) are progressive disorders that can cause lower uri-
nary tract symptoms (LUTS) and ultimately lead to acute
urinary retention (AUR) or the need for prostatic surgery
[1]. Predictors for disease progression are age, symptom
status, post-void residual volume, maximum Xow rate
(Qmax) and—currently most widely used—prostate vol-
ume with prostate speciWc antigen (PSA) as a proxy
parameter [2]. Progression risk assessment is used in
contemporary medical BPH management treatment algo-
rithms [3].
Long-term treatment with 5-reductase inhibitors
(5ARIs) results in a 50% risk reduction for AUR or the
need for surgery indicating that the disease progression can
be altered by medical therapy [4, 5]. The magnitude of this
eVect is dependent on various parameters, such as prostate
volume. The prostate cancer (PCa) prevention trial (PCPT)
has also shown that long-term treatment with Wnsterid in
healthy men without LUTS leads to a favourable outcome
regarding several BPH-parameters (AUR, need for surgery,
urinary tract infection) thus supporting the concept of a pre-
ventive strategy [6].
The development of LUTS in men is a multifactorial
process with multiple factors involved, such as BPH, BPE,
BPO, inXammatory processes in the prostate, changes in
detrusor function, alterations of the peripheral and central
nervous system and—potentially—genetic factors. A
genetic marker predictive for the development of BPE,
BPO or LUTS would be a major improvement for preven-
tive strategies and patient management. In contrast to clini-
cal parameters such as prostate volume or PSA, genetic
markers would allow a much earlier risk assessment with
earlier and potentially more eVective intervention, e.g. by
5ARIs.
Polymorphisms of genes involved in the testosterone
metabolism are currently under intense evaluation as bio-
markers for PCa risk [7, 8]. The CYP19A1 gene is located
on chromosome 15 (15q21.1) and encodes the enzyme aro-
matase catalysing the irreversible conversion of andro-
stenedione to estrone and testosterone to estradiol [8].
Aromatase is present in the gonads and in the extragonadal
tissue, including the prostate and adipose tissue [8]. Aroma-
tase mRNA and protein have both been detected in BPH
and PCa tissue. Polymorphisms in the CYP19A1-gene
showed borderline increased risks for PCA [8]. CYP3A4 is
located on chromosome 7 (7q21.1) and involved in the oxi-
dation of testosterone to 2-, 6- or 15-hydroxytestoster-
one, which is biologically less active than testosterone or
dihydroxytestosterone [8]. A variant in the 5 untranslated
region of CYP3A4 (rs2740574) has been associated with
PCa risk in some studies and also in men with a history of
BPH [9].
The known importance of androgens for the pathogene-
sis of BPH/BPE, the potential role of CYP19A1 and
CYP3A4 genes in the androgen metabolism and association
of both polymorphisms to PCa risk prompted us to investi-
gate the association of genetic polymorphisms in the
CYP19A1 and CYP3A4 genes, to several clinical and labo-
ratory BPH-parameters in a population-based sample
(Herne LUTS study). Neither of these polymorphisms has
been previously tested for their association to clinical BPH-
parameters.
Materials and methods
The design of the Herne LUTS study has been outlined
elsewhere [10]. In brief, this is a population-based study
that was initiated in 1999 in the city of Herne, Germany. Of
the 8,973 men on the mailing list, 60.2% (n =5 , 4 0 4 )  c o m -
pleted the initial questionnaire and underwent a detailed
urological examination. For the current analysis all men
meeting the following criteria were eligible: serum PSA
<10 ng/ml, age 50–79 years and a prostate volume
<100 ml.
Of a subset of men who entered the Herne LUTS study
whole blood serum samples were stored suitable for DNA
extraction. This sample of 392 men entered the current
study. At baseline all participants underwent a detailed clin-
ical investigation with assessment of the following parame-
ters: International Prostate Symptom Score (IPSS), free
uroXow study, post-void residual volume (PVR), prostate
volume by transrectal ultrasound (TRUS) and a serum PSA
analysis. All PSA analyses were performed by the same
PSA-test.
The presence of PCa was carefully excluded by digito-
rectal examination and serum PSA analysis. All men with a
suspicious Wnding on digital rectal examination (DRE) and/
or serum PSA >4.0 ng/ml underwent TRUS guided biopsy
and were only included if the biopsy was negative. Serum
androgen levels were not determined.
Genotyping
Genomic DNA was extracted from peripheral blood
using QIAamp Blood Midi Kit (QIAgen, Hilden,
Germany). The polymorphisms were determined by
5-nuclease TaqMan assays with ABI PRISM 7500
sequence detection system. The reaction contained 20 ng
genomic DNA, TaqMan 2£ PCR Master Mix, forward
and reverse primers and probes for the wild-type and the
mutant allele in a total volume of 10 l. Universal reac-
tion conditions were 2 min at 50°C, 10 min at 95°C, 40
cycles with 15 s at 92°C and annealing/extension at 60°C
for 1 min. Allelic discrimination was carried out by mea-
surement of Xuorescence yields of the two diVerent dyes
at 60°C.World J Urol (2011) 29:143–148 145
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Statistical analyses
Linear regression models were estimated for parameters
IPSS, prostate volume, Qmax and PSA, respectively. Step-
wise backward regression was applied to select polymor-
phisms that were used to generate the Wnal model. At each
step, Akaike’s information criterion (AIC) was calculated
to decide if the polymorphism with the smallest eVect was
dropped from the model. Age was included as confounder
in all four models. Polymorphisms considered as regressors
were rs700518, rs1004 and CYP3A. Statistical procedures
were calculated by the computer software SPSS (Chicago,
IL) for Windows (version 6.0.1) and Epi Info (version
6.04c, Centers for Disease Control and Prevention, Atlanta,
GA). Descriptive analyses included Student’s t test of
means and standard deviations. Results were considered to
be statistically signiWcant when P <0 . 0 5 ;  a l l  P values were




Principal characteristics of the study population (n = 392)
are listed in Table 1. These data suggest a typical popula-
tion of elderly men generated via population-based sam-
pling.
Cyp19A1 gene polymorphism
All polymorphisms were distributed in the Hardy–Wein-
berg equilibrium.
Two polymorphisms in the CYP19A1 gene [rs700518 in
exon 4 (A57G); rs10046 in the 3UTR (C286T)] were
determined (Table 2). The rs700518-AA genotype was
present in 96 (24.5%), the heterozygotous in 194 (49.5%)
and the homozygous GG genotype in 102 men (26%).
IPSS, Qmax, prostate volume and PSA were similar across
all rs700518 genotypes (Table 2).
The rs10046 CC-genotype was present in 91 men
(23.2%), the heterozygous in 190 (48.5%) and the homozy-
gous TT-genotype in 111 men (28.3%). IPSS, Qmax and
prostate volume were similar across rs10046 genotypes
(Table 2). Men carrying the heterozygotous genotype had
higher PSA levels (2.0 § 0.1 ng/ml) than those carrying the
wild-type genotype (1.7 § 0.2 ng/ml, P = 0.012); this level
of signiWcance remained after adjustment for multiple
testing. This diVerence, however, was lost in men carrying
both mutated alleles, i.e. lacked a “gene dose-response”
(Table 2).
Cyp3A4 gene polymorphism
The AA genotype was present in 360 men (91.8%) and the
heterozygous genotype (AG) in 32 men (8.2%); no one had
the homozygous GG genotype (Table 3). There was no
association between the CYP3A4 gene polymorphism and
IPSS and the Qmax (Table 3). Prostate volume was larger in
men carrying the wild-type genotype [32.1 § 0.8 (range
25–87 ml) vs. 27.0 § 2.0 (range 26–78 ml), P = 0.02]. In
parallel, men carrying the AA genotype had a signiWcantly
higher serum PSA (1.9 § 0.1 ng/ml) than those with one G
allele (1.6 § 0.3 ng/ml,  P = 0.046). This level of signiW-
cance was lost after adjustment for multiple testing ( value
0.017).
Discussion
Polymorphisms of genes involved in the androgen pathway
hold promise as biomarkers for PCa, for review see [7, 8].
However, the association between androgen pathway gene
polymorphisms and PCa risk is complex and characterized
by contradictory results [7, 8]. The cause of this conXict in
any particular association of genotype and phenotype is
diYcult to identify and it can be attributable to biological,
statistical and technical causes.
Relatively little is known regarding the potential role of
gene polymorphisms for the development of BPH/BPE.
Although cellular origins of BPH/BPE and PCa are diVer-
ent, both diseases are under comparable endocrine and may
be under similar genetic control.
Several reasons render genetic markers for BPE clini-
cally relevant: (1) high prevalence of the disease, (2) demo-
graphic trends towards ageing in upcoming decades, (3)
availability of medical therapies (5ARI) known to alter the
natural history to the disease and (4) BPE is an important
prognosticator for LUTS-related complications. Men with
prostates >30 ml have a threefold increase in the risk of
AUR and a fourfold increase in the risk of undergoing
BPH-related treatment compared to men with smaller
Table 1 Principal cohort characteristics (n = 392)
Mean SD Min Max
Age (years) 65.4 7.0 52 79
IPSS 7.5 5.8 0 29
Qmax (ml/s) 15.4 8.5 2 48
Prostate volume (ml) 31.1 12.1 10 99
PSA (ng/ml) 1.8 1.8 0.12 9.9146 World J Urol (2011) 29:143–148
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prostates [1, 2]. In addition larger prostates have a higher
mean annual growth rate than smaller ones [1, 2].
Our study has two strengths: Wrst, we have investigated a
population-based, representative sample of elderly men,
hence our cohort is not biased by referral patterns; sec-
ondly, all men in this study underwent a detailed urological
investigation with exclusion of PCa. Although it well estab-
lished that around 20% of men have PCa in the <4.0 ng/ml
PSA-range based on the PCPT, the cut-oV used herein
(4.0 ng/ml) is clinically established. It is unrealistic to pro-
pose routine prostate biopsies in a population-based sam-
ple. Population-based samples, which are not carefully
screened with this respect, carry the risk of being contami-
nated with PCa cases. A limitation is the rather small sam-
ple size; the down-side of using a population-based cohort
is that the number of men with severe LUTS and signiW-
cantly impaired Xow rates is limited.
This is the Wrst study that has investigated the associa-
tion of polymorphisms within CYP19A1 and CYP3A4
genes to BPH-parameters. The CYP19A1 gene on 15q21.1
codes for aromatase that converts C19 androgens into aro-
matic C18 oestrogenic steroids [8]. Hence, up-regulation of
this enzyme may lead to an increase in oestrogen produc-
tion. The oestrogen-dominant status in men after middle
age has been implicated in the induction and progression of
BPH [11]. The recent data suggest that aromatase expres-
sion in prostatic stromal cells is induced by prostaglandin E
vis a paracrine mechanism [11]. However, functional tests
in the CYP19A1 gene showed no signiWcant changes in
protein activity or level compared with the WT enzyme
after transient expression in COS-1 cells [8]. Studies corre-
lating several polymorphisms in the CYP19A1 gene to PCa
yielded conXicting results with the majority being negative
[7, 8]. This is in line with the current study: the rs700518
polymorphisms showed to correlation to clinical BPH-
parameters, the rs10046 revealed a weak correlation to
PSA. While the latter remained signiWcant after adjustment
for multiple testing, it is noteworthy that there was no
“gene dose-response”, i.e. that homozygous TT carriers had
values intermediate those of CC and CT carriers. This lack
of a dose-response eVect is diYcult to explain and could be
also due to inter- and intraindividual PSA variations. It is
worth to note that the diVerences observed were small
being in the range of these PSA variations.
Moreover, the PSA Wndings were not mirrored by those
on prostate volume although it is generally assumed that
PSA is a good proxy parameter for prostate volume.
Human CYP3A4 is the major CYP enzyme for testoster-
one deactivation [7, 8]. CYP3A4 has also been shown to be
involved in the regulation of cell proliferation and diVeren-
tiation in prostate cells. A G>A mutation located in the
P450NF (nifedipine oxidase) speciWc element has been
identiWed that disrupts a transcriptional regulatory element
located in the 5 regulatory region of CYP3A4 [8]. The
reported frequency of this alteration shows clear ethnic/
geographic diVerences, reXecting the PCa rate, which high-
est in African-American men, intermediate in Caucasian
men and lowest in Asian men [8]. Association with higher
clinical stage and grade has been reported, although contra-
dictory reports also exist [8]. The current analysis revealed
Table 2 Association between 
two polymorphisms in the 
Cyp19A1-gene and BPH-
parameters
Parameter RS 700518 P value
A/A (n = 96) A/G (n = 194) G/G (n = 102)
IPSS 8.0 § 0.6 7.4 § 0.4 7.4 § 0.6 NS
Qmax (ml/s) 15.7 § 0.9 15.3 § 0.6 15.3 § 0.9 NS
Prostate vol. (ml) 31.6 § 1.5 31.3 § 0.9 31.4 § 1.7 NS
PSA (ng/ml) 1.7 § 0.2 2.0 § 0.1 1.9 § 0.2 NS
Parameter RS 10046 P value
C/C (n = 91) C/T (n =1 9 0 ) T / T  ( n = 111)
IPSS 8.0 § 0.07 7.5 § 0.4 7.2 § 0.6 NS
Qmax (ml/s) 15.7 § 0.9 15.3 § 0.6 15.4 § 0.9 NS
Prostate vol. (ml) 31.6 § 1.6 31.4 § 1.0 31.3 § 1.5 NS
PSA (ng/ml) 1.7 § 0.2 2.0 § 0.1* 1.8 § 0.2 CC versus C/T: 0.012 CC 
versus TT: NS
Numbers indicate 
mean + standard error of the 
mean
* P = 0.012
Table 3 Association between a CYP3A4 gene polymorphism and
BPH-parameters
Numbers indicate mean + standard error of the mean
Parameter A/A (n =3 6 0 ) A / G  ( n =3 2 ) P value
IPSS 7.6 § 0.3 6.6 § 0.9 NS
Qmax (ml/s) 15.4 § 0.5 15.9 § 1.5 NS
Prostate vol. (ml) 32 § 0.8 27 § 2.0 0.02
PSA (ng/ml) 1.9 § 0.1 1.6 § 0.3 0.046World J Urol (2011) 29:143–148 147
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no statistically association (after adjustment for multiple
testing) of a CYP3A4-polymorphism to clinical BPH-
parameters.
Several other polymorphisms in the androgen pathway
have been correlated to clinical BPH-parameters. Four
studies have determined the association of the number of
CAG-repeats within the androgen receptor (AR) to prostate
volume [12–15]. Three studies, including a previous one
from our group analysing a typical BPH-population (men
referred for TURP), were negative [12–15]. Giovannucci
et al. [16] reported on an association of the number of
CAG-repeats within the AR to prostate volume and risk for
prostate surgery.
Four studies addressed the potential role a polymor-
phism within the 17 hydroxylase (CYP17) gene, one of the
key enzymes in testosterone biosynthesis to several BPH-
parameters [17–20]. While two studies observed no associ-
ation to hormone levels, our group observed a lower
stroma/epithelial cell ratio in individuals carrying the
mutated allele [17, 18]. In a Turkish cohort, Gunes et al.
[19] observed an association between this polymorphism
and BPH. By analysing a population-based Chinese cohort,
Madigan et al. [20] failed to identify a clear association
between CYP17 polymorphism and BPH-parameters.
The potential role of polymorphisms within the 5
reductase gene (SRD5A2) in the development of BPH/BPE
has also been addressed [13,  21,  22]. An association to
serum testosterone levels has been observed in both studies
analysing the SRD5A2 V89L polymorphism; larger pros-
tates and higher PSA levels were correlated to the SRD5A2
A49T genotype [13]. Salam et al. [22] reported on a non-
signiWcant association between the SRD5A2 V89L poly-
morphism and BPH, yet noticed a signiWcant association
for Hispanics.
In conclusion, all these studies—including the current
one—yielded conXicting data which is in part due to diVer-
ent study designs (cross-sectional, longitudinal), diVerent
study populations (surgical cases, outpatients, population-
based cohorts, screening populations) and BPH-deWnitions
(prostate volume, Qmax, need for surgery). Many human
traits and their underlying polymorphic genes show inde-
pendent patterns of racial, ethnic and geographic variation.
Understanding the importance of polymorphisms in the
androgen pathway genes still requires more studies. A pre-
disposition caused by a combination of genetic variants, of
which each carries a small relative risk, may be of much
greater signiWcance. Hence, this understanding can only
emerge if research extends beyond single gene studies to
encompass gene–gene and gene–environment interaction
studies. The inconsistent associations observed herein war-
rant further studies. In general, the data regarding the asso-
ciation of gene polymorphism to LUTS, prostate volume,
uroXowmetry and PSA suggest that this disease is caused
by multiple rather than a single genetic variant. If this is
true, it becomes unlikely that any single gene polymor-
phisms will exhibit a strong enough correlation with BPH-
parameters and/or progression risk to be clinically useful.
ConXict of interest statement There is no conXict of interest.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution Noncommercial License which permits any
noncommercial use, distribution, and reproduction in any medium,
provided the original author(s) and source are credited.
References
1. Emberton M (2003) The hallmarks of BPH progression and risk
factors. Eur Urol 22(suppl 8):2–7
2. Roehborn CG (2008) BPH progression: concept and key learnings
from MTOPS, ALTESS, COMBAT, and ALF-ONE. BJU Int
101(suppl 3):17–21
3. Madersbacher S, Alivizatos G, Nordling J, Sanz CR, Emberton M,
de la Rosette JJMCH (2004) EAU 2004 guidelines on assessment,
therapy and follow-up of men with lower urinary tract symptoms
suggestive of benign prostatic obstruction (BPH guidelines). Eur
Urol 46:547–554
4. McConnell JD, Bruskewitz R, Walsh P (1998) The eVect of Wnas-
teride on the risk of acute urinary retention and the need for surgi-
cal treatment among men with benign prostatic hyperplasia.
Finasteride Long-Term EYcacy and Safety Study Group. N Engl
J Med 338:557–563
5. Debruyne F, Barkin J, van Erps P, Reis M, Tammela TLJ,
Roehborn C, on behalf of the ARIA3001, ARIA3002 and
ARIB3003 Study Investigators (2004) EYcacy and safety of long-
term treatment with the dual 5-reductase inhibitor dutasteride in
men with symptomatic benign prostatic hyperplasia. Eur Urol
46:488–495
6. Thompson IM, Goodman PJ, Tangen CM et al (2003) The inXu-
ence of Wnasteride on the development of prostate cancer. N Engl
J Med 349:215–224
7. Gsur A, Feik E, Madersbacher S (2004) Genetic polymorphisms
and prostate cancer risk. World J Urol 21:414–423
8. Mononen N, Schleutker J (2009) Polymorphisms in genes
involved in androgen pathways as risk factors for prostate cancer.
J Urol 181:1541–1549
9. Tayeb MT, Clark C, Sharp L et al (2002) CYP3A4 promoter vari-
ant is associated with prostate cancer risk in men with benign pros-
tate hyperplasia. Oncol Rep 9:653–655
10. Berges R (2008) Epidemiology of benign prostatic syndrome:
associated risks and management data in German men over age 50.
Urologe A 47:141–148
11. Wu Q, Zhou Y, Chen L et al (2007) Benign prostatic hyperplasia
(BPH) epithelial cell line BPH-1 induces aromatase expression in
prostatic stromal cells via prostaglandin E2. J Endocrinol 195:89–94
12. Bousema JT, Bussemakers MJG, van Houwelingen KP et al
(2000) Polymorphisms in the vitamin D receptor gene and the
androgen receptor gene and the risk of benign prostatic hyperpla-
sia. Eur Urol 37:234–238
13. Schatzl G, Madersbacher S, Gsur A et al (2002) Association of
polymorphisms within androgen receptor-, 5-reductase- and
PSA-genes with prostate volume, clinical parameters and endo-
crine status in elderly men. Prostate 52:130–138
14. Mitsumori K, Terai A, Oka H et al (1999) Androgen receptor CAG
repeat length polymorphism in benign prostatic hyperplasia
(BPH): correlation with adenoma growth. Prostate 41:253–257148 World J Urol (2011) 29:143–148
123
15. Shibata A, Stamey TA, McNeal JE, Cheng I, Peehl DM (2001)
Genetic polymorphisms in the androgen receptor and type II
5-reductase genes in prostate enlargement. J Urol 166:1560–1564
16. Giovannucci E, Platz EA, Stampfer MJ et al (1999) The CAG
repeat within the androgen receptor gene and benign prostatic
hyperplasia. Urology 53:121–125
17. Schatzl G, Gsur A, Bernhofer G et al (2001) Association of
vitamin D receptor and 17 hydroxylase gene polymorphisms with
benign prostatic hyperplasia and benign prostatic enlargement.
Urology 57:567–572
18. Allen NE, Forrest MS, Key TJ (2001) The association between
polymorphisms in the CYP17 and 5alpha-reductase (SRD5A2)
genes and serum androgen concentrations in men. Cancer Epidem-
iol Biomarkers Prev 10:185–189
19. Gunes S, Bagci H, Sarikaya S, Bilen CY, Kara N (2007) Prostate-
speciWc antigen and 17-hydroxylase polymorphic genotypes in
patients with prostate cancer and benign prostatic hyperplasia.
DNA Cell Biol 26:873–878
20. Madigan MP, Gao YT, Deng J et al (2003) Cyp17 polymorphisms
in relation to risks of prostate cancer and benign prostatic hyper-
plasia: a population-based study in China. Int J Cancer 107:271–
275
21. Allen NE, Forrest MS, Key TJ (2001) The association between
polymorphisms in the CYP17 and 5alpha-reductase (SRD5A2)
genes and serum androgen concentrations in men. Cancer Epidem-
iol Biomarkers Prev 10:185–189
22. Salam MT, Ursin G, Skinner EC, Dessissa T, Reichardt JK (2005)
Associations between polymorphisms in the steroid 5-alpha reduc-
tase type II (SRD5A2) gene and benign prostatic hyperplasia and
prostate cancer. Urol Oncol 23:246–253